GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » YoY Rev. per Sh. Growth

TTNP (Titan Pharmaceuticals) YoY Rev. per Sh. Growth : -100.00% (As of Jun. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Titan Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 was -100.00%.

Titan Pharmaceuticals's Revenue per Share for the three months ended in Jun. 2024 was $0.00.

Titan Pharmaceuticals YoY Rev. per Sh. Growth Historical Data

The historical data trend for Titan Pharmaceuticals's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals YoY Rev. per Sh. Growth Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -98.74 -65.59 -82.08 -82.58 -98.88

Titan Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.00 -100.00 -100.00 - -100.00

Titan Pharmaceuticals YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Titan Pharmaceuticals's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0.001-0.089)/ | 0.089 |
=-98.88 %

Titan Pharmaceuticals's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Jun. 2024 )
=(Revenue per Share (Q: Jun. 2024 )-Revenue per Share (Q: Jun. 2023 )) / | Revenue per Share (Q: Jun. 2023 )) |
=(0-0.001)/ | 0.001 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Pharmaceuticals YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
DWTX ONCT TSOI OGEN INM NBY PKTX ENVB SNPX BPTH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Website
https://www.titanpharm.com
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Executives
Seow Gim Shen 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd. 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo director 1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey director 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg director 710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi director 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe director, officer: President and COO 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong 10 percent owner NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar director, 10 percent owner, officer: Chief Executive Officer VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc other: Member of 10% owner group 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers director 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin director, officer: Executive Chairman C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg officer: See Remarks 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080